Briacell Therapeutics -CW27BCTXWPreferred / convertible
13F holders, Q4 2024 (December 31)4holders
0new positions
0sold out
$0.28avg. 13F price*
At the end of Q4 2024, 4 institutions reported holding Briacell Therapeutics -CW27 (BCTXW) in their 13F filings, unchanged from Q3 2024. 0 opened new positions and 0 sold out. The largest holders were Armistice Capital, LLC ($109K), Redmond Asset Management, LLC ($18K) and UBS Group AG ($2K).
- Company
- Briacell Therapeutics -CW27
- CUSIP
- 10778Y112
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 22,645 shares sold, net −22,645 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Armistice Capital, LLC | — | No change | 375,000 | $109K |
| Redmond Asset Management, LLC | — | No change | 75,000 | $18K |
| UBS Group AG | — | Reduce -77.9% | 6,413 | $2K |
| Osaic Holdings, Inc. | — | No change | 800 | $192 |
"% of holder's portfolio" is BCTXW's weight in each manager's 13F, not the share of Briacell Therapeutics -CW27 the manager owns.